The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a freeze on U.S.-funded ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

Some people are fair-weather friends; others are lifelong. It's a similar story with stocks. Some you might hold only ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Novo Nordisk A/S (NVO) stock saw a decline, ending the day at $84.45 which represents a decrease of $-0.89 or -1.04% from the prior close of $85.34. The stock opened at $84.87 and touched a low of $84 ...

The Novo Nordisk Foundation continues to prioritize its focus on non-communicable diseases despite a global health crisis prompted by the U.S. freeze on foreign aid. With substantial assets, the ...

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

As a whole, the list of top 50 most admired companies in 2025 saw four new entrants, namely Caterpillar (#40), ServiceNow ...

King Frederik stepped out for the official royal engagement to witness the big initiative after announcing his diplomatic ...

Anyone who’s looked at the market in the last couple of weeks will know that there were some events that shook investors.